Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Journal of Pharmaceutical Sciences
|
April 1, 1996
NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data
P B Laub, J M Gallo
Protein Science : a Publication of the Protein Society
|
May 1, 1995
Localized solution structure refinement of an F45W variant of ubiquitin using stochastic boundary molecular dynamics and NMR distance restraints
P B Laub, S Khorasanizadeh, H Roder
Nature Structural Biology
|
November 1, 1995
NMR structure of an inhibitory R2 C-terminal peptide bound to mouse ribonucleotide reductase R1 subunit
A Fisher, P B Laub, B S Cooperman
Biochemistry
|
September 28, 1993
A noncovalent peptide complex as a model for an early folding intermediate of cytochrome c
L C Wu, P B Laub, G A Elöve, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2001
Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose
P J O'Dwyer, C Szarka, J M Brennan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2000
Population pharmacokinetic model for topotecan derived from phase I clinical trials
J M Gallo, P B Laub, E K Rowinsky, et al.
Cancer Research
|
March 1, 1997
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines
S W Johnson, P B Laub, J S Beesley, et al.
Biochemistry
|
October 4, 2000
Structure-based optimization of peptide inhibitors of mammalian ribonucleotide reductase
M Pellegrini, S Liehr, A L Fisher, et al.
Cancer Research
|
October 15, 1995
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO
J M Gallo, J Brennan, T C Hamilton, et al.
British Journal of Cancer
|
February 24, 2005
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells
D Roberts, J Schick, S Conway, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Journal of Pharmaceutical Sciences
|
April 1, 1996
NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data
P B Laub, J M Gallo
Protein Science : a Publication of the Protein Society
|
May 1, 1995
Localized solution structure refinement of an F45W variant of ubiquitin using stochastic boundary molecular dynamics and NMR distance restraints
P B Laub, S Khorasanizadeh, H Roder
Nature Structural Biology
|
November 1, 1995
NMR structure of an inhibitory R2 C-terminal peptide bound to mouse ribonucleotide reductase R1 subunit
A Fisher, P B Laub, B S Cooperman
Biochemistry
|
September 28, 1993
A noncovalent peptide complex as a model for an early folding intermediate of cytochrome c
L C Wu, P B Laub, G A Elöve, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 13, 2001
Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose
P J O'Dwyer, C Szarka, J M Brennan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2000
Population pharmacokinetic model for topotecan derived from phase I clinical trials
J M Gallo, P B Laub, E K Rowinsky, et al.
Cancer Research
|
March 1, 1997
Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines
S W Johnson, P B Laub, J S Beesley, et al.
Biochemistry
|
October 4, 2000
Structure-based optimization of peptide inhibitors of mammalian ribonucleotide reductase
M Pellegrini, S Liehr, A L Fisher, et al.
Cancer Research
|
October 15, 1995
Time-dependent pharmacodynamic models in cancer chemotherapy: population pharmacodynamic model for glutathione depletion following modulation by buthionine sulfoximine (BSO) in a Phase I trial of melphalan and BSO
J M Gallo, J Brennan, T C Hamilton, et al.
British Journal of Cancer
|
February 24, 2005
Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells
D Roberts, J Schick, S Conway, et al.
Page
of 2